← Back to Clinical Trials
Recruiting Phase 4 NCT07116564

NCT07116564 Impact of ERAS Protocol on Length of Hospital Stay After Laparoscopic Surgeries

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07116564
Status Recruiting
Phase Phase 4
Sponsor Aga Khan University
Condition ERAS
Study Type INTERVENTIONAL
Enrollment 98 participants
Start Date 2025-08-20
Primary Completion 2026-08-01

Eligibility & Interventions

Sex Female only
Min Age 20 Years
Max Age 60 Years
Study Type INTERVENTIONAL
Interventions
Enhanced Recovery After SurgeryControl

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.

This trial targets 98 participants in total. It began in 2025-08-20 with a primary completion date of 2026-08-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this clinical trial is to determine the length of hospital stay in patients using multimodal analgesia with or without ERAS protocol scheduled for elective laparoscopic gynecological surgeries

Eligibility Criteria

Inclusion Criteria: * ASA physical status I, II, and III * Patients scheduled for elective laparoscopic gynecological surgeries Exclusion Criteria: * Refusal to participate * History of allergy or contraindication to study drugs * Patients in which procedure converted to open surgery * Diagnostic laparoscopic procedures * Patients with a history of severe anxiety or depression

Contact & Investigator

Central Contact

Ali Sarfraz Siddiqui, MBBS, MCPS, FCPS, FIPP, MHPE

✉ sarfraz.siddiqui@aku.edu

📞 +922134864397

Frequently Asked Questions

Who can join the NCT07116564 clinical trial?

This trial is open to female participants only, aged 20 Years or older, up to 60 Years, studying ERAS. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

What phase is the NCT07116564 trial and what does that mean for participants?

Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.

Is NCT07116564 currently recruiting?

Yes, NCT07116564 is actively recruiting participants. Contact the research team at sarfraz.siddiqui@aku.edu for enrollment information.

Where is the NCT07116564 trial being conducted?

This trial is being conducted at Karachi, Pakistan.

Who is sponsoring the NCT07116564 clinical trial?

NCT07116564 is sponsored by Aga Khan University. The trial plans to enroll 98 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology